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Abstract 22 
Moderate temperature hyperthermia (40-45C for one hour) is emerging as an effective 23 
treatment to enhance best available chemotherapy strategies for bladder cancer. A rapidly 24 
increasing number of clinical trials have investigated the feasibility and efficacy of treating 25 
bladder cancer with combined intravesical chemotherapy and moderate temperature 26 
hyperthermia. To date, most studies have concerned treatment of non-muscle invasive bladder 27 
cancer (NMIBC) limited to the interior wall of the bladder. Following the promising results of 28 
initial clinical trials, investigators are now considering protocols for treatment of muscle invasive 29 
bladder cancer (MIBC). This paper provides a brief overview of the devices and techniques 30 
used for heating bladder cancer. Systems are described for thermal conduction heating of 31 
bladder wall via circulation of hot fluid, intravesical microwave antenna heating, capacitively 32 
coupled RF current heating, and radiofrequency phased array deep regional heating of the 33 
pelvis. Relative heating characteristics of the available technologies are compared based on 34 
published feasibility studies, and the systems correlated with clinical requirements for effective 35 
treatment of MIBC and NMIBC. 36 
 37 
Introduction 38 
The purpose of this paper is to review the capabilities of various heating technologies available 39 
for treatment of bladder cancer, with an eye toward correlating typical performance 40 
characteristics of each approach with the clinical requirements. Bladder tumors present either 41 
as non-muscle invasive (NMIBC), 70%, or as muscle invasive (MIBC), 30%, carcinomas.(1) 42 
While most clinical studies to date have concerned treatment of NMIBC superficial disease 43 
limited to the interior wall of bladder,(2-7) future clinical trials must address the more aggressive 44 
MIBC that extends beyond the bladder wall out into surrounding pelvic tissues.  Thus depending 45 
on the extent of disease, heating systems are required to accomplish different clinical goals of 46 
treatment.   47 
 48 
For healthy persons, the mean bladder wall thickness  is 3.0±1 mm and 3.3±1.1 mm for female 49 
and male respectively with a weak positive correlation between wall thickness and age.(8)  50 
According to current staging criteria, NMIBC cancers encompass all Tis, Ta, and T1 bladder 51 
tumors that are limited to the mucosa and submucosa, i.e. involving less than 1 mm penetration 52 
into the bladder wall. Hence, if adequate transurethral resection of the intrabladder tumor growth 53 
has taken place prior to treatment, the therapeutic temperatures (40-43°C) of the hyperthermia 54 
treatment should target a depth of about 1 mm in order to produce heat activation of intravesical 55 
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chemotherapy. For MIBC, i.e. tumor stages T2-T4a, the hyperthermia target extends to much 56 
greater depths and a heating system for MIBC must be able to deposit significant power 57 
throughout the bladder wall and for some patients out into extravesical pelvic tissues to enhance 58 
the delivery and activation of systemically administered chemotherapeutic throughout the 59 
muscle invasive component of disease. 60 
 61 
 62 
Figure 1. Pictorial of bladder cancer staging classification as regards penetration of disease into the 63 
bladder wall. Reprinted with permission from Katelaris Urology, http://www.katelarisurology.com.au/about-64 
bladder-cancer/. 65 
 66 
The different tumor pathology of NMIBC and MIBC must be reflected in the clinical practice of 67 
applying adjuvant hyperthermia and thus the requirements on technology for heating these two 68 
diseases are quite different. For NMIBC with Tis, Ta, and T1 tumors, the target to be heated is 69 
well defined (~1 mm deep) and the technological demands for adequate heating of such shallow 70 
depth tumors are relatively easily met with uncomplicated thermal conduction heating solutions. 71 
For MIBC however, the tumor is ill-defined and variable in depth, size, shape and location 72 
(especially the advanced cases) demanding much higher flexibility in power deposition 73 
capabilities of the hyperthermia system to adequately heat the desired target volume.  For this 74 
situation, effective use of heating technology is critically dependent on treatment planning, 75 
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temperature measurement, and feedback control strategies. The modeling and thermal 76 
dosimetry approaches used to monitor and guide these complex treatments will be addressed in 77 
another paper of this special issue. Similarly, the clinical requirements for treating NMIBC and 78 
MIBC will be described in accompanying papers that summarize specific procedures and clinical 79 
results of the most common bladder treatment approaches.  This special issue also includes 80 
specific coverage of the biological effects of hyperthermia, the pharmacologic effects of heat 81 
activated drug therapy, and the immunological effects of adjuvant hyperthermia.   82 
 83 
In this overview, we describe the currently available methods for heating both NMIBC and MIBC 84 
disease, as well as their basic physical principles. Based on the available literature, we compile 85 
a semi-quantitative table to compare performance attributes of each technology. Finally, this 86 
summary information is organized to provide clinicians with an overview of pros and cons of the 87 
alternative approaches to heat NMIBC and MIBC, to aid the selection of hyperthermia method 88 
that best matches the tumor target.      89 
 90 
Devices and Techniques for Clinical Heating of Bladder Cancer 91 
The available technology for heating bladder cancer differs greatly in principle of heating, 92 
technological complexity, labor resources, preparation time, quality assurance demands, and 93 
cost. Transfer of energy may occur by direct thermal conduction, electromagnetic (EM) fields, or 94 
ultrasound (US) waves. Each of these technologies requires quite specific clinical and technical 95 
procedures that produce unique depth of penetration and uniformity of temperature.(9-12) The 96 
following paragraphs briefly describe the general characteristics, limitations and benefits of each 97 
heating method. To our belief, we have included all currently available clinical approaches. In 98 
our attempt to provide meaningful data for comparison of heating techniques in Table 2, we tried 99 
carefully to avoid inclusion of duplicate patient data from published feasibility studies. A 100 
common challenge is to accurately monitor the temperature distribution of the entire tumor as it 101 
invades different depths into the bladder wall, especially in the case of more extensive MIBC 102 
disease. Temperature gradients in the target volume occur due to variable local blood perfusion 103 
and to heterogeneity of absorbed energy from the heat source. Appropriate thermal dosimetry 104 
procedures are covered in another paper of this special issue.  105 
 106 
Radiative EM energy based external heating  107 
Principles:   108 
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Typical radiofrequency (RF) phased array applicators operating between 70 and 120 MHz 109 
produce a large hot spot at the phase focus but also heat skin and a significant portion of pelvic 110 
tissue outside the focus. Heating patterns possible with electromagnetic phased array 111 
applicators have been studied extensively.(13-17)  Located centrally in the pelvis and filled with 112 
a mixture of lossy urine and drug that has no blood perfusion cooling, the bladder heats 113 
preferentially using an appropriately phased array of RF antennas around the torso to focus 114 
power deposition in and around the bladder. A 14-patient Phase I clinical trial was conducted to 115 
study the feasibility of treating NMIBC with intravesical Mitomycin C (MMC) combined with 116 
external radiofrequency phased array deep hyperthermia.(6) The thermal dosimetry of that 14 117 
patient trial showed that adequate heating, defined as a bladder temperature above 40°C for 118 
more than 40 min, was achieved in 96% of the treatments, and 73% of the patients completed 119 
the  course of 10 treatments per protocol.(18)  A subsequent 18 patient trial using the 120 
Amsterdam AMC-4 or AMC-8 waveguide system (17) produced similar results, demonstrating 121 
feasibility of heating NMIBC with low toxicity using an external electromagnetic phased array.(3)   122 
Excellent bladder temperatures were achieved (i.e. an average bladder temperature of 41.6°C 123 
for 60-90 min each treatment) with 83% completing the six induction treatments and 50% 124 
completing all 10 treatments. Since the diffuse focus produced by 70-120 MHz phased array 125 
systems is larger than the bladder dimensions, this heating approach deposits power not only in 126 
the bladder contents but also directly in the bladder wall and tissues surrounding the bladder. 127 
Thus, these electromagnetic heating approaches can be expected to heat the entire bladder 128 
wall and potentially muscle invasive disease extending outside the bladder.  To date, no large 129 
trials of MIBC have been reported, but the feasibility of heating locally advanced MIBC has been 130 
demonstrated in a small study of 5 patients.(19)  This study showed that interstitially measured 131 
tumor temperatures correlated with intraluminal measured temperatures (average tumor 132 
temperature 40.9±1.1°C vs tumor indicative bladder lumen temperature 40.7±1.3°C). These 133 
feasibility studies suggest that the RF deep heating approach is suitable for heating bladder 134 
cancers extending into the pelvis, especially when combined with MR thermal monitoring to 135 
define the 3D temperature distribution throughout the pelvis in real time during treatment.(20-22)  136 
Since most centers do not have MR thermal monitoring capability yet, control of the treatment 137 
relies more heavily on careful treatment planning whenever the tumor target extends 1 cm or 138 
more from the typical bladder and rectal temperature monitoring sites.  Software is available for 139 
patient specific treatment planning of deep heat treatments, such as Sigma HyperPlan (Dr 140 
Sennewald Medizintechnik GmbH, Munich, Germany), a program that was optimized 141 
specifically for the BSD2000 Sigma applicators. The utility of this comprehensive planning 142 
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program looks very promising but overall accuracy in complex tissue regions like the pelvis is 143 
still under evaluation.(23-26) Other multi-physics software is available commercially that is 144 
flexible for modeling power deposition and corresponding thermal heat transfer in the body from 145 
any applicator, such as SEMCAD X (SPEAG, Zurich Switzerland), HFSS (Ansys Corp, 146 
Canonsburg PA, USA), COMSOL Multi-Physics (Comsol Inc., Burlington MA, USA), CST Studio 147 
Suite (CST, Framingham MA, USA), and others.  The value of these powerful electromagnetic 148 
and thermal modeling programs is currently under evaluation. See accompanying article in this 149 
special issue on thermal dosimetry and treatment planning.(27) 150 
Temperature measurement during radiative electromagnetic heating of bladder cancer is often 151 
performed by a single catheter using multiple sensor temperature sensors or by thermal 152 
mapping.(3, 6, 18, 19)  Recently, Cordeiro et al. (28) introduced a special catheter to improve 153 
the quality of temperature measurement during NMIBC hyperthermia. Once in the bladder, the 154 
catheter unfolds like an umbrella and places three temperature sensors against the bladder wall 155 
equally distributed around the circumference. 156 
Typical EM deep heating systems  157 
The BSD2000 RF Phased Array Hyperthermia System (Pyrexar Corp., Salt Lake City UT, USA) 158 
powers 1-3 annular rings of dipole antennas with phase adjustable signals in the range of 80-159 
120 MHz. Several applicator configurations are available for treatment of pelvic disease. A four 160 
channel system powers four twin dipole antennas spaced around either a 60 cm diameter 161 
annular array (Sigma 60 applicator), or a smaller 57 x 40 cm elliptical array (Sigma Ellipse).(14-162 
16)  The BSD2000 3D and 3D/MR Hyperthermia Systems include an elliptically shaped Sigma 163 
Eye applicator that is MR compatible to fit inside a 60 cm dia MR magnet.(21, 22)  The Sigma 164 
Eye applicator includes three coaxial rings of four twin dipole radiators, for a total of 24 165 
antennas driven with the 12 power channels at a frequency of 100 MHz. The system takes 166 
advantage of custom software that obtains 3D thermal image data during treatment to provide 167 
realtime feedback to the 12 independent phase and amplitude controls.(20, 22, 29, 30)  All 168 
Sigma applicators have a flexible silicone membrane inside the applicator that inflates like an 169 
annular doughnut shape around the torso and fills with circulating temperature controlled 170 
deionized water to cool the skin and couple electric field into the patient.    171 
 172 
Deep regional heating of large regions in the pelvis may be accomplished similarly with a 70 173 
MHz radiofrequency phased array system (AMC-4 or -8) using either 1 or 2 rings of 4 174 
waveguide antennas, each with an aperture size of 33 x 21 cm and temperature controlled 175 
7 
 
waterbolus coupling to the patient.(3, 17, 31).  While the single ring 4 antenna system has been 176 
used successfully in a clinical trial to heat bladder disease,(3) recent studies indicate that the 3D 177 
SAR steering of the AMC-8 system promises an enlarged SAR focal region as well as improved 178 
control and localization of heating.(17, 32)  The 70 MHz four antenna system is now available 179 
commercially as the Alba 4D (Alba Hyperthermia Systems, Roma Italy). 180 
 181 
Capacitively coupled external electric current heating 182 
Principles:   183 
Using lower frequency RF such as 8 - 13.56 MHz, electromagnetic energy may be delivered to 184 
tissue via electric current that flows between capacitively coupled electrodes on the skin 185 
surface.  All currently available systems have two electrodes that are generally coupled to the 186 
skin with electrically conductive temperature controlled saline pads to conduct and spread 187 
electric current into tissue and cool the skin surface.(33-35)  Electrical current must flow through 188 
the high resistance fat tissue layer before splitting into multiple current paths through the 189 
intervening tissue between electrodes. Thus, maximal power deposition normally occurs in the 190 
superficial fat layer which must be cooled with temperature regulated saline bolus.(36, 37) At 191 
depth, electrical currents distribute such that more current flows through low resistance tissues 192 
like muscle and tumor, and less current flows in parallel through high resistance tissues like fat, 193 
bone and aerated lung.(33, 38)  With power deposition proportional to the current squared, 194 
more power is deposited in tissues along the higher current pathways in low resistance tissues. 195 
Thus power deposition is possible in low resistance urine filled bladder even though maximum 196 
heating rate likely occurs in the high resistance superficial fat layer just under the electrodes. 197 
Using different size electrodes, RF currents and tissue heating may be concentrated under the 198 
smaller electrode. Ongoing clinical use primarily in Asia has demonstrated the ability to heat into 199 
the hyperthermic range in patients with sufficiently thin layers of high resistance fat tissue 200 
overlying tumor, using aggressive skin cooling.(5, 37, 39)  201 
 202 
Two clinical studies report on the performance of capacitively coupled hyperthermia to heat 203 
locally advanced MIBC.  Masunaga et al. (40) reports that an average intravesical bladder 204 
temperature of 41.5±1.1°C was obtained in their group of 28 patients. They also indicate that 205 
significantly higher bladder temperatures were achieved in patients with a subcutaneous fat 206 
layer less than 2 cm thickness. The average duration of the heat treatment was 44.4±8 min for 207 
patients with an average bladder temperature >41.5°C, and 40.5±5.9 min for patients with 208 
bladder Tavg <41.5°C.  Uchibayashi et al (41) analyzed the ability to heat locally advanced 209 
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muscle invasive bladder tumors in 46 patients. They report similar findings: intravesical and 210 
tumor temperatures could be raised to 42.5°C or higher for patients with subcutaneous fat 211 
layers less than 2 cm thickness. In obese patients, it was more difficult to heat the bladder tumor 212 
to the required level. Thermometry was performed using Teflon coated thermocouples placed in 213 
the ureter, rectum and tumor. Patient complaints concerned pain at the edge of the electrodes in 214 
nearly half of the patients, and was the limiting factor for power elevation in these patients.  215 
 216 
Typical heating systems: 217 
Capacitively coupled RF heating systems are available with two  moveable capacitive plate 218 
electrodes around a treatment bed such as the 13.56 MHz 600 W Celsius TCS system (Celsius 219 
42+ GmbH, Cologne Germany), and two electrodes mounted on a parallel opposed rotating arm 220 
as in the 8 MHz Thermotron RF-8 (Yamamoto Vinyter, Japan).(35, 36)    221 
 222 
Ultrasound energy based external heating  223 
Principles:  224 
Several ultrasound array devices have been designed for hyperthermia treatment of large deep 225 
tissue targets.(42-44)  However the majority of focused ultrasound applications involve smaller 226 
target volumes that take advantage of the short wavelength to produce tightly focused hot spots 227 
for rapid thermal ablation without effecting surrounding normal tissues.(45, 46) With care to 228 
manage reflections and absorption of ultrasound near air and bone, the small hot spot can be 229 
shifted to produce successive overlapping regions to treat larger volumes such as human 230 
bladder.  While ultrasound travels through urine without much loss, power can be focused on 231 
the bladder wall itself to produce effective localization of heat in specific tumor target regions. 232 
The challenge of this technique is in designing the scanning algorithm that provides 233 
homogenous bladder wall heating. Although the feasibility of heating bladder with ultrasound 234 
has been demonstrated,(47) large tissue targets in the pelvis are generally heated using 235 
electromagnetic phased array sources having longer wavelengths that both penetrate and 236 
produce larger bladder-sized focal zones. At present no commercial systems are available that 237 
are optimized for bladder treatment and no clinical studies have been reported.   238 
 239 
 240 
Radiative EM energy based internal heating: Intravesical Microwave Antenna 241 
Principles:  242 
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As an alternative to localizing heat in bladder from external sources, one can radiate energy 243 
from a small diameter intraluminal microwave antenna inserted into the bladder through a 244 
special multilumen urethral catheter. The advantage of this method is that energy does not 245 
travel through a large volume of normal tissue before impinging on the bladder target, but is 246 
instead aimed directly at the adjacent tumor target from inside the bladder. In addition, well 247 
localized heating around the intravesical antenna can be achieved with rather simple equipment 248 
compared to external phased array sources. Further, the use of microwave radiation increases 249 
the penetration of effective heating in perfused tissue of the bladder wall in comparison to 250 
thermal conduction only heat sources.  Microwave antennas that can be placed inside 1-2 mm 251 
diameter catheters have been investigated by many groups and the principles and typical 252 
radiation patterns have been reviewed previously.(48)  The first system optimized for use inside 253 
the bladder applies power to a 915 MHz coaxial cable antenna that is introduced into the 254 
bladder inside a special Foley catheter and radiates an EMF into tissue around the antenna tip.  255 
Because fluid inside the bladder is circulated around the antenna and through an external 256 
temperature controlling heat exchanger, heat is removed from the fluid during treatment 257 
enabling use of higher antenna power levels without overheating the fluid.  This allows the 258 
microwave field to penetrate further through the electrically lossy urine/drug filled bladder to 259 
deposit energy directly in the bladder wall.  260 
 261 
Of all hyperthermia systems used for heating NMIBC, intravesical microwave heating has the 262 
highest number of clinical studies performed. The eight studies reported in Table 1 are not 263 
exhaustive; however they cover 287 patients treated by four different institutions and hence 264 
provide strong endorsement for the clinical viability of intravesical microwave antenna 265 
heating.(2, 49-54) The largest reported study of this approach by Nativ et al. (55) is a 266 
retrospective analysis of 111 NMIBC patients. Overall the clinical experience with intravesical 267 
microwave heating demonstrates that therapeutic temperatures (42±2°C) are routinely achieved 268 
inside the bladder, though the median temperature and temperature range vary substantially 269 
between institutes. In general, the studies indicate that heat treatments are well-tolerated with a 270 
high proportion of patients completing the entire treatment course. Reported adverse events are 271 
mostly local and transient such as pain and bladder spasm during treatment sessions, followed 272 
by hematuria, dysuria and transient incontinence. It should be noted that typical intravesical 273 
microwave  systems measure temperature at three different points along the inner wall of 274 
bladder, providing a small but representative sampling of achieved intra-bladder 275 
temperatures.(28, 51) The relatively large temperature range reported can be explained by the 276 
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non-uniform irradiation pattern of an interstitial microwave antenna in an irregular shaped fluid-277 
filled bladder. This non-uniform power deposition pattern is also associated with the relatively 278 
high incidence of thermal reactions seen in the posterior bladder wall. 279 
  280 
Typical intravesical microwave antenna system: 281 
The Synergo SB-TS 101 System (Medical Enterprises Europe B.V., Amstelveen, The 282 
Netherlands) consists of a 915 MHz microwave applicator that is inserted into the bladder via a 283 
special multilumen 19.5F or 20F catheter. A peristaltic pump slowly circulates MMC through the 284 
catheter into the bladder through a temperature controlled heat exchanger that cools the drug 285 
and helps homogenize intrabladder temperature during application of microwave power. 286 
Temperatures are measured in the urethra and with three thermocouples pressed against the 287 
bladder wall by the inflated catheter balloon.(4, 51) 288 
 289 
Intravesical Thermal Conduction Heating 290 
Principles:  291 
The most straightforward approach to heating tissue is to apply a heated surface in intimate 292 
contact with the target tissue to enable heat transfer across a thermal gradient. To uniformly 293 
heat the interior wall of a complex shaped bladder cavity, this simple heat transfer approach is 294 
best accomplished by vigorously circulating externally heated fluid (and drug) at a controlled 295 
temperature throughout the bladder. Due to the dynamics of turbulent flow, there is a non-296 
uniform velocity profile across the inner bladder surface but with sufficient circulation the entire 297 
target tissue on the inner wall of bladder will come in contact with rapidly moving near equi-298 
temperature fluid. With no power deposition directly in tissue, the resulting temperature 299 
distribution is dependent only on bladder tissue thermal parameters rather than heterogeneous 300 
electrical or acoustic tissue properties. Using thermal conduction only heating, maximum tissue 301 
temperature is readily determined with confidence to be the measured input temperature of the 302 
circulating fluid, and thus thermal toxicity is easily avoided.  The constant temperature interface 303 
should provide relatively uniform heating of the inner surface of bladder even with 304 
heterogeneous thermal properties that effect heat penetration into the wall.  While temperature 305 
of the bladder lumen may be nearly constant, there is a steep temperature gradient within the 306 
bladder wall as heat dissipates rapidly into surrounding cooler tissues. Especially because of 307 
heat losses to normothermic blood perfusing the bladder wall tissues, the penetration depth of 308 
effective heating is limited when the driving thermal gradient is only 7C (44 - 37C). The 309 
accompanying modeling and thermal dosimetry paper in this special issue specifically 310 
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addresses penetration of heat into the bladder wall with various heating technologies. Previous 311 
studies of temperature gradients in perfused tissue adjacent to a hot (or cold) surface show that 312 
the effective heating potential of a 7C thermal gradient extend no more than 2-3 mm deep.(56, 313 
57). For NMIBC cancers that extend <2mm into the bladder wall, this thermal gradient induced 314 
heating should be sufficient for effective treatment. Clinical experience at three institutes using 315 
two different intravesical thermal conduction heating systems indicates excellent performance 316 
with a very high percentage of patients completing the prescribed treatment course (see Table 317 
1). 318 
  319 
Alternatively, thermal conduction heating from inside the bladder may be accomplished without 320 
the need to circulate expensive chemotherapeutic through multi-lumen connecting tubes to an 321 
external temperature regulating heat exchanger.  Efforts are underway to investigate the use of 322 
ferromagnetic nanoparticle (MNP) solutions that can be mixed with drug and injected into the 323 
bladder through a standard Foley catheter. With this approach, the MNP are heated via 324 
magnetic induction coupling from an externally applied alternating magnetic field, usually at a 325 
frequency of 50-100 kHz to minimize direct eddy current heating in the pelvis.  As demonstrated 326 
in preclinical studies, the MNP can produce sufficient heating to raise the temperature of the 327 
chemotherapeutic mixture in bladder to the desired treatment temperature.(58) Inductively 328 
coupled heating is distributed throughout the MNP solution producing relatively homogeneous 329 
internal bladder temperature, and convection current mixing of bladder contents further 330 
minimizes temperature gradients during treatment. For magnetic coupled nanoparticle solutions, 331 
temperature must be monitored with a probe inserted into the bladder through the Foley 332 
catheter. Unlike the rapidly circulated heated fluid approach, the maximum bladder temperature 333 
is not known precisely as the intraluminal probe will generally underestimate the peak 334 
temperature due to small gradients within the unstirred magnetic fluid/chemotherapeutic 335 
mixture.     336 
 337 
Typical intravesical thermal conduction systems: 338 
There are two commercial systems that heat bladder by circulating heated drug through the 339 
bladder.  The Combat BRS System (Combat Medical Ltd – Wheathampstead, Herts UK) heats 340 
chemotherapeutic (e.g. MMC) to the desired intrabladder temperature in the range of 40-44C 341 
and circulates the heated drug through the bladder via a soft and flexible 16F 3-way catheter 342 
with coude tip to facilitate insertion into the bladder.(59) The device consists of a temperature 343 
controlled waterbath heat source and peristaltic pump to circulate drug through the bladder via a 344 
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low volume high efficiency heat exchanger. Temperature of the circulating fluid is monitored with 345 
an inline probe and all treatment parameters are controlled via a simple touch screen user 346 
interface with graphical temperature display and safety alarms for high and low temperature, 347 
and overpressure.   348 
The Unithermia System (Elmedical Ltd, Hod-Hasharon Israel) for Bladder Wall Thermo-349 
chemotherapy  uses a similar design concept to heat chemotherapeutic to about 46.5C in order 350 
to obtain 44-44.5C drug temperature inside the bladder using a circulation rate that achieves 351 
approximately 4 exchanges of bladder fluid contents per minute.(60, 61)  This rapid circulation 352 
of drug within the bladder improves the uniformity of drug temperature contacting the inner 353 
surface of bladder and provides fresh drug to the bladder wall surface continuously for the 354 
typical 50 min thermochemotherapy treatment. 355 
 356 
Devices and Techniques for Pre-Clinical Bladder Heating  357 
Preclinical studies are often used in the development and optimization of new cancer treatment 358 
strategies. Rodent studies are most common though larger animals are also used to model the 359 
human treatment situation more closely. Since human bladder capacity is approximately 500 360 
ml,(62) the small size of bladder in mice (~ 0.15 ml) and rats (~ 1 - 1.5 ml) requires different 361 
heating systems(58, 63). Farm pigs are also used for preclinical studies, with bladder volumes 362 
ranging from 250 ml to larger than human bladders. Thus preclinical studies require unique 363 
heating technology that can localize heat within the desired bladder target which may be buried 364 
over 3 to 12 mm from the skin surface. Hyperthermia studies are often performed in mice using 365 
simple thermal conduction heating via waterbath, but that approach generally produces regional 366 
if not systemic temperature rise that would complicate interpretation of biologic response to 367 
specific bladder therapy. In recent years, a number of approaches have been reported for 368 
improved localization of heat in animal bladders. 369 
 370 
Radiative external microwave antenna heating  371 
In order to elevate temperature in a urine filled bladder at depths of 3-8 mm below the skin of 372 
small animals like mice and rats, microwave antenna systems have been developed at 915 MHz 373 
and 2450 MHz. These antennas are generally 1-2 cm in diameter and coupled to tissue with a 374 
temperature controlled waterbolus to cool the superficial tissues and allow localization of heat in 375 
underlying bladder. Salahi et al. describe the heating performance of a 1 cm diameter water 376 
filled circular waveguide microwave antenna designed specifically for heating small rodent 377 
bladders.(63) Another microwave antenna designed for small volume heat treatments has been 378 
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reported previously (64, 65) with heating patterns that demonstrate feasibility of treating small 379 
animal bladders. Snow et al. report the feasibility of heating in vivo pig bladder with no acute 380 
toxicity using a small array of 915 MHz square slot dual concentric conductor antennas.(66, 67) 381 
 382 
Inductively coupled ferromagnetic nanoparticle heating  383 
An increasing body of literature describes the use of ferromagnetic nanoparticles (MNP) injected 384 
into a tumor directly or administered systemically with the goal of concentrating sufficient 385 
magnetic material in the target to heat tissue from coupling to an externally applied magnetic 386 
field. For NMIBC disease where the target tissue is located < 2 mm deep into the bladder wall, 387 
the injection of magnetic fluid into the bladder intermixed with chemotherapeutic and 388 
subsequent heating of bladder via external magnetic field seems straightforward. Oliveira et al. 389 
(58) report a feasibility study of introducing a concentrated magnetic fluid into rat bladder via 390 
urethral catheter and heating the bladder by magnetic field coupling to the ferrofluid. With no 391 
forced stirring, thermal gradients will occur inside the bladder. However, homogenization of 392 
intrabladder temperatures is anticipated due to natural convective stirring of bladder contents 393 
driven by the small thermal gradients. 394 
 395 
Gold nanoparticle enhanced photothermal ablation 396 
Another area of development involves laser or electric field coupled heating of gold 397 
nanoparticles.(68)   Cho et al.(69) describe a treatment approach involving photothermal 398 
ablation of superficial bladder cancer. They propose to fill the bladder with a solution of gold 399 
nanorods conjugated to anti-EGFR antibodies that will bind to EGFR-expressing bladder cancer 400 
cells. Then by introducing near infrared radiation to the interior of the bladder via a modified 401 
cystoscope, power may be deposited preferentially in the gold nanorods sufficient to thermally 402 
ablate adjacent tumor cells. 403 
 404 
Correlation of Heating Technologies with Clinical Requirements  405 
General characteristics of the clinical problem 406 
As explained earlier, there are primarily two types of disease to be addressed in this review: 407 
NMIBC and MIBC.  These two diseases are quite different biologically and anatomically, and 408 
require significantly different treatment approaches. The corresponding requirements for heating 409 
these two diseases are also quite different.  Superficial bladder cancers involve only the mucosa 410 
and sub-mucosa layers along the inner bladder surface, generally with a thickness <2 mm.  On 411 
the other hand, MIBC by definition extends into the muscle layers of the bladder wall and even 412 
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into extravesical structures outside the bladder; this deeper disease presents a wide range of 413 
technical challenges to effective heating. Thus optimal heating of NMIBC requires 414 
homogeneous heating of the bladder interior extending < 2-3 mm into the bladder wall, and 415 
ideally there would be minimal heating of normal tissues outside the bladder. Optimal treatment 416 
of MIBC requires heating not only the bladder wall but also a variable amount of tissue outside 417 
the bladder.  Of all the available heating  technology, some systems are better suited to limiting 418 
the extent of heating to just a thin rim of target disease on the interior of the bladder, and other 419 
devices are better suited to heating large regions of pelvis including bladder and surrounding 420 
tissues.  421 
Criteria for determining effectiveness of treatment include: 422 
Homogeneity of heating around the interior surface of bladder 423 
Depth of penetration of heating through bladder tissue 424 
Circulation/mixing of drug in contact with inner surface of bladder wall 425 
Heating of normal tissue outside the bladder  426 
Heating of tumor tissue outside the bladder  427 
Ease of heating 428 
Patient tolerance 429 
 430 
Clinical infrastructure requirements 431 
In addition to comparing technological performance of the above mentioned systems by 432 
characterizing their ability to localize and uniformly heat tumor, other important considerations 433 
for selecting a hyperthermia system include the initial capital investment, space, supplies, and 434 
personnel and time required to prepare for and apply each treatment.  435 
 436 
Of the intravesical systems, the circulating fluid thermal conduction method is the most 437 
straightforward to apply. Due to the known maximum temperature of the circulating fluid, this 438 
approach has the lowest risk of side effects from uncontrolled excessive temperature. It also is 439 
the least demanding of resources for calibration and quality assurance validation. The 440 
intravesical microwave antenna system is similarly compact, but includes a power generator 441 
that produces non-uniform power deposition around the antenna and unknown temperature 442 
peaks in tissue.  Thus this technology requires stepwise more quality assurance and personnel 443 
training to obtain safe and reproducible performance. In either case, the intravesical systems 444 
should be applied only for heating superficial NMIBC. 445 
 446 
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External RF hyperthermia systems require a more substantial infrastructure to purchase and 447 
maintain the equipment, and to provide appropriate RF shielding for non-ISM band EMF. The 448 
technology for capacitively coupled electric current systems is relatively straight forward and 449 
maintenance with minimal QA verification measurements should be sufficient for safe 450 
operational use. A consequence of the relatively simple capacitive plate technology is a lack of 451 
flexibility to adjust power deposition pattern for optimal tumor heating and to effectively 452 
accommodate patient complaints with minor adjustments of heating parameters. In comparison, 453 
the external RF radiative systems use the most complex technology and require the most 454 
extensive support structure. The advantage is that they are the only systems that can heat both 455 
NMIBC and MIBC disease. And with carefully designed treatment protocols, heating of NMIBC 456 
has been demonstrated with acceptable personnel resources, i.e. with only one person to 457 
operate the system. If the bladder is filled with a high absorbing liquid, preferential heating can 458 
be obtained with predefined antenna settings and without extensive hyperthermia treatment 459 
planning. Investing in a radiative EMF method should be considered when there is a need to 460 
apply hyperthermia to locally advanced muscle invasive bladder tumors. In that application, 461 
heating of MIBC should be performed using optimal antenna settings obtained by patient 462 
specific hyperthermia treatment planning, and with the deep hyperthermia system operated 463 
following appropriate quality assurance guidelines.(70-73)   464 
 465 
Pros and Cons of Bladder Heating Technologies 466 
A summary of advantages and disadvantages is provided in Table 2 for each of the heating 467 
technologies described above. For treatment of NMIBC limited to the interior of bladder, 468 
intravesical heating approaches appear most appropriate. As illustrated before, the simplest 469 
way to heat bladder wall tumors is via the circulating, heated fluid approach. This has the 470 
advantage of knowing both the maximum temperature anywhere in tissue and effective extent of 471 
heating is limited to about 2-3 mm maximum penetration through the bladder wall, which is 472 
sufficient for NMIBC. Thus, circulating fluid thermal conduction heating may be expected to 473 
produce fewer toxicities compared to more complicated microwave heating approach that is 474 
known to produce non-homogeneous power deposition with "hot spots”  and potentially burns in 475 
the posterior bladder wall and "cold spots” or places of ineffective heating at the dome and near 476 
the trigone. Potential advantages of the intravesical microwave thermo-chemotherapy approach 477 
stem from the increased penetration of microwave energy into somewhat thicker tumors (3-6 478 
mm) and the use of circulating cooled drug to limit indiscriminant heating particularly in the 479 
bladder neck and urethra. This claim may be overstated however, as the precooled drug 480 
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solution is heated during circulation both in the multilumen catheter where drug flows slowly 481 
through the same catheter with a hot radiating microwave antenna and in the bladder where the 482 
drug surrounds the radiating antenna. Thus, although improved penetration of heating may be 483 
possible using the intravesical microwave antenna, significant thermal gradients are produced 484 
within the bladder as well as the tumor due to non-uniform power deposition from the antenna 485 
and slow circulation of fluid in the multilumen catheter.   486 
 487 
Although external electromagnetic heating systems are more complex than intravesical devices, 488 
there are potential advantages that result from the more complete heating of bladder, bladder 489 
wall, and tissues surrounding the bladder, which may prove important for long term clinical 490 
response. Obvious weaknesses of external regional heating approaches stem from the lack of 491 
knowledge of peak temperatures and hot spots in tissue, and inclusion of significant volumes of 492 
normal tissue within the heated region. Current pilot studies have demonstrated the feasibility of 493 
using external RF systems to effectively heat NMIBC with minimal toxicity,(3, 6, 18) but the 494 
determination of any advantage in terms of clinical outcome awaits larger clinical trials.  495 
  496 
Summary 497 
This review outlines the clinical requirements for heating bladder as a component of 498 
thermochemotherapy for bladder cancer. Devices and techniques currently available to heat 499 
bladder are described briefly and the equipment correlated with most appropriate clinical 500 
disease, either muscle invasive bladder cancer or non-muscle invasive bladder cancer.  501 
Representative commercially available clinical equipment systems are identified for each type of 502 
energy delivery. And several systems are described within the context of pre-clinical heating 503 
equipment currently available for use in animal studies. This article is intended to supplement 504 
the detailed descriptions of clinical disease, biological goals of treatment, clinical trial results, 505 
thermal dosimetry and treatment planning descriptions that are contained in other articles of this 506 
special issue on bladder cancer.  507 
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Table 1:  Comparison chart of clinical studies of bladder hyperthermia  516 
 517 
 518 
Table 2:  Relative heating characteristics of clinical bladder hyperthermia systems     519 
 520 
+ + Major Advantage,  + Moderate Advantage ,   -  Moderate Shortcoming,  - - Major 521 
Shortcoming  522 
  523 
Equipment Reference
Frequency 
(MHz)
Study Size
Prescribed            
# Tx
Treatment           
Schedule
Ave Power [W] 
or Temp [°C]
Goal/Achieved 
Temperature 
HT                              
Duration
Goal Treatment    
Completed
Max Toxicity                        
(CTCAE score)
Most Common Toxicity
  External Deep Regional RF
       BSD-2000 RF Phased Array HT System
Inman 2014 (6)            
Juang 2014 (24)
80-120 14 10
6 x 1/wk +                  
4 x 1/ mon
740 ± 162W
96% > 40 min at 
Tmin>40°C
Ave Time >40C    
53.1 ± 8.8 min
73% Grade 2 
40% Foley Cath Pain                             
33% Abdomenal Discomfort
       BSD-2000 RF Phased Array HT System Fatehi 2007 (25) 75-80 5 NR 1/wk NR
40.9°C tumor         
40.7 °C lumen
60-90 min NR NR NR
       AMC-4, AMC-8 Waveguide Phased Array System Geijsen 2015 (3) 70 18 10
6 x 1/wk +                  
4 x 1/mon
553W T50 = 41.6°C 60 - 90 min
83% Induction   
50% Full
Grade 2 
38% Local Pain and                
Bladder Spasms
  Capacitive Plate Electrodes
       Yamamoto Vinyter - RF-8  Capacitive Heating System Masunaga 1994 (41) 8 28 4  2/wk + RT 578 + 86W   42.1 + 8.0°C 35 - 60 min 43% Pain Under Electrodes
       Yamamoto Vinyter - RF-8  Capacitive Heating System Uchibayashi 1995 (42) 8 46 6 -10  2/wk + RT 42.5°C 60 Grade 2
28% Burn, 24% Anorexia                   
20% Sub-Q Induration
  Intravesical Microwave Antenna  
        Synergo SB-TS 101 Transurethral MW System Colombo 1995 (44) 915 44 8 2/wk in <6 wks < 60 W 42.5 - 44.5°C
60 min Goal                                               
>40 min Minimum
97% NR
Mild Urge and                         
Urethral Burning
        Synergo SB-TS 101 Transurethral MW System Colombo 1996 (45) 915 29 6 - 8
1-2/wk in                   
<6 wks
NR 42.5 - 46°C
60 min (2 x 30 min          
to Refresh Drug)
93% Grade 3 Mild Urgency
        Synergo SB-TS 101 Transurethral MW System Colombo 1998 (46) 915 19 8 1/wk NR 42.5 - 46°C
60 min Goal            
>40 min Minimum
96% NR
Moderate/Severe  
Urgency, Mild Urethral Burning
        Synergo SB-TS 101 Transurethral MW System Colombo 2003 (2) 915 42 12
8 x 1/wk +                  
4 x 1/ mon
NR 42 ± 2°C
60 min (2 x 30 min           
to Refresh Drug)
88% NR
Pelvic Pain and  Posterior Wall 
Thermal Reaction
        Synergo SB-TS 101 Transurethral MW System Kiss 2015 (47) 915 21 6 - 12 NR  42 ± 2°C
60 min (2 x 30 min          
to Refresh Drug)
62%
Grade 4                                     
CTC Score - NCIC
57% Pain and Bladder Spasms
        Synergo SB-TS 101 Transurethral MW System Maffezzini 2014  (48) 915 42 14
4 x 1/wk +                  
6 x 2/mon +                 
4 x 1/mon
NR 42.5 ± 1.5°C
60 min Goal                    
>40 min Minimum
76% Grade 2
100%  Thermal Reaction                     
Posterior Bladder Wall
        Synergo SB-TS 101 Transurethral MW System
van der Heijden 2004 
(49)
915 90 10 - 14
6-8 x 1/wk +                     
4-6 x 1/mon
NR 41 - 44°C
60 min (2 x 30 min           
to Refresh Drug)
10 ± 2 
Toxicity All Local         
Healed Spontaneously
72%  > 1 Toxicity                             
100% Thermal Reaction              
Posterior Bladder Wall 
        Synergo SB-TS 101 Transurethral MW System Nativ 2009 (50) 915 111 12
6 x 1/wk +                  
6 every 4-6 wks
NR 42 ± 2°C
60 min (2 x 30 min          
to Refresh Drug)
95% Grade 3 31% Pain and Bladder Spasms
  Intravesical Thermal Conduction
       Combat Medical Ltd – Combat BRS System Sousa 2014 (54) - 15 8 8 x 1/wk 43 ± 1°C
Bladder Temp         
Not Measured
96% - 60 min           
99% > 40 min
99% Grade 2 
33% Irritative                                         
Lower Urinary Tract
       Elmedical Ltd - Unithermia System Ekin 2015 (55) - 43 12
6 x 1/wk +                  
3 x 1/wk in                    
months 3 and 6
NR
Bladder Temp        
Not Measured
60 min 93%
Grade 5                                 
Institutional CTC Score
37% Noninfective Cystitis
       Elmedical Ltd - Unithermia System Soria 2015 (56) - 34 6 6 x 1/wk
42.5 ± 1°C              
44.5°C Peak
Bladder Temp         
Not Measured
45 min 88% Grade 3 24% Bladder Spasms
Heating
Deep Regional Deep Focused Capacitive Microwave Circulating
Criterion Electromagnetic Ultrasound  Current Heated Fluid
  Homogeneity of heating around interior wall of bladder + _  _ _ _  _ + + 
  Depth of penetration of heating through tissue + + + + + + _ _  _
  Control of maximum temperature _  _ _ _  _ _ + +
  Circulation/mixing of drug in contact with bladder wall _ _ _ + + +
  Heating of tumor tissue outside the bladder + + + + _ _  _
  Heating of normal tissue outside the bladder _  _ _ _  _ + + +
  Ease of Heating _ _  _ _ _ + +
  Patient Tolerance _ _ _ _ +
External Intravesical
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